These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30371242)

  • 1. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk.
    Toth PP; Granowitz C; Hull M; Liassou D; Anderson A; Philip S
    J Am Heart Assoc; 2018 Aug; 7(15):e008740. PubMed ID: 30371242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Mayo Clin Proc; 2019 Sep; 94(9):1670-1680. PubMed ID: 31405751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.
    Toth PP; Granowitz C; Hull M; Anderson A; Philip S
    Lipids Health Dis; 2019 Sep; 18(1):175. PubMed ID: 31526399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
    Boekholdt SM; Arsenault BJ; Hovingh GK; Mora S; Pedersen TR; Larosa JC; Welch KM; Amarenco P; Demicco DA; Tonkin AM; Sullivan DR; Kirby A; Colhoun HM; Hitman GA; Betteridge DJ; Durrington PN; Clearfield MB; Downs JR; Gotto AM; Ridker PM; Kastelein JJ
    Circulation; 2013 Oct; 128(14):1504-12. PubMed ID: 23965489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
    N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
    Sirimarco G; Labreuche J; Bruckert E; Goldstein LB; Fox KM; Rothwell PM; Amarenco P;
    Stroke; 2014 May; 45(5):1429-36. PubMed ID: 24736236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis.
    Toth PP; Philip S; Hull M; Granowitz C
    Clin Cardiol; 2019 Oct; 42(10):908-913. PubMed ID: 31368589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol Control for Subclinical Coronary Atherosclerosis in Subjects Without Indication for Statin Therapy.
    Park HW; Kim YG; Park GM; Park S; Cho YR; Suh J; Lee Y; Yang DH; Kang JW; Kim HK; Choe J; Kim YH; Lee SW
    Am J Cardiol; 2021 Aug; 153():51-57. PubMed ID: 34176598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
    Mora S; Glynn RJ; Ridker PM
    Circulation; 2013 Sep; 128(11):1189-97. PubMed ID: 24002795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Cardiorenal Med; 2019; 9(6):400-407. PubMed ID: 31450229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study.
    Omote K; Yokota I; Nagai T; Sakuma I; Nakagawa Y; Kamiya K; Iwata H; Miyauchi K; Ozaki Y; Hibi K; Hiro T; Fukumoto Y; Mori H; Hokimoto S; Ohashi Y; Ohtsu H; Ogawa H; Daida H; Iimuro S; Shimokawa H; Saito Y; Kimura T; Matsuzaki M; Nagai R; Anzai T
    J Atheroscler Thromb; 2022 Jan; 29(1):50-68. PubMed ID: 33431716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triglyceride and Triglyceride/ HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease.
    Prasad M; Sara J; Widmer RJ; Lennon R; Lerman LO; Lerman A
    J Am Heart Assoc; 2019 May; 8(9):e009442. PubMed ID: 31014162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence.
    Toth PP; Fazio S; Wong ND; Hull M; Nichols GA
    Diabetes Obes Metab; 2020 Mar; 22(3):279-289. PubMed ID: 31742844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
    Nichols GA; Philip S; Reynolds K; Granowitz CB; Fazio S
    Diabetes Obes Metab; 2019 Feb; 21(2):366-371. PubMed ID: 30225881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Vasc Health Risk Manag; 2019; 15():533-538. PubMed ID: 31824165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
    Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease.
    Wong ND; Zhao Y; Sung J; Browne A
    Am J Cardiol; 2021 Apr; 145():12-17. PubMed ID: 33454339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.